Thank you for Subscribing to Life Science Review Weekly Brief
Sana Biotechnology, Inc. enters into a lease agreement to construct a 163,000-square-foot manufacturing facility in Fremont, California.
FREMONT, CA: Sana Biotechnology, Inc., a business focused on developing and commercializing modified cells as pharmaceuticals, signs a leasing agreement to create a 163,000-square-foot manufacturing facility in Fremont, California. This facility will be used to manufacture Sana's late-stage clinical development and early commercial product candidates across the company's diverse technology platforms.
“Manufacturing remains a key bottleneck to the development and broad accessibility of cell- and gene-based medicines. This facility is a key component in enabling our aspirations to rapidly innovate, consistently manufacture, and scale production of these medicines,” says Steve Harr, Sana's President and CEO. “Sana is making significant investments to create the scientific insights, supply chain stability, and operational capabilities to transform the potentially disruptive scientific insights of the cell and gene therapy field into important medicines for patients.”
The Fremont location puts Sana's existing technical and scientific capabilities within easy reach and provides access to a strong biotechnology talent pool. The facility produces allogeneic T cells, viral vectors, and pluripotent stem cells. Sana also wants to cooperate with contract manufacturing partners to push its product candidates to the clinic as early as next year, as part of the company's holistic manufacturing approach.
Sana Biotechnology, Inc.'s mission is to develop and distribute modified cells to patients as medications. We share a vision of repairing and managing genes, replacing missing or damaged cells, and disseminating our remedies. We are a team of over 300 people dedicated to building an enduring company that transforms how the world addresses disease. Sana operates out of Seattle, Cambridge, and San Francisco's South Bay.